Filing Flows › Roivant Sciences (ROIV) › Q1 FY26
Roivant Sciences (ROIV) Q1 FY26 earnings results (first quarter fiscal 2026)
10-Q filed Aug 11, 2025
Roivant Sciences (ROIV) reported revenue of $2.2M for the first quarter fiscal 2026 (Q1 FY26), -73% from a year earlier and -71% from the quarter before.
Roivant Sciences, Q1 FY26: revenue $2.2M (-73% year over year), net loss $274M, operating cash flow −$204M. The chart follows the revenue to costs, profit and cash.
| Q1 FY26 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $2.2M | -71% | -73% |
| Operating profit | −$285M | — | — |
| Net earnings | −$274M | — | — |
| Operating cash flow | −$204M | — | — |
What changed
Revenue was $2.2M in Q1 FY26, down 73% year over year and down 71% from the previous quarter.
Operating costs exceeded revenue by $284.9M, an operating margin of -13130.0%. Total costs grew 160% against a revenue fall of 73%. The quarter ended with a net loss of $273.9M, wider than the previous quarter's $252.4M loss. Minority interests bore $50.6M of it: to shareholders the quarter was a loss of $223.4M.
Operating cash flow was −$204.4M. Non-cash charges added back $1.1M of depreciation and amortization and $82.2M of share-based compensation. Working capital and other items used $13.7M. Capital expenditures of $4.0M exceeded it, leaving free cash flow of −$208.4M.
Questions
What was Roivant Sciences' revenue in the first quarter fiscal 2026?
Roivant Sciences (ROIV) reported revenue of $2.2M for the first quarter fiscal 2026 (Q1 FY26), -73% from a year earlier and -71% from the quarter before.
Source: Roivant Sciences 10-Q on SEC EDGAR.